Xiaodong Wang Sells 41,760 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $262.82, for a total transaction of $10,975,363.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, May 13th, Xiaodong Wang sold 41,760 shares of Beigene stock. The stock was sold at an average price of $223.50, for a total value of $9,333,360.00.
• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of Beigene stock. The stock was sold at an average price of $242.66, for a total value of $10,133,481.60.
• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $261.28, for a total value of $10,911,052.80.

Beigene Stock Performance

Beigene stock opened at $269.63 on Friday. Beigene, Ltd. has a fifty-two week low of $141.31 and a fifty-two week high of $287.88. The stock has a market cap of $31.92 billion, a P/E ratio of -32.72, a PEG ratio of 7.73 and a beta of 0.30. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $241.38.

Beigene (NASDAQ:ONC) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. As a group, analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, April 21st. TD Securities reaffirmed a “buy” rating and issued a $334.00 price target on shares of Beigene in a report on Thursday, April 24th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada decreased their price target on Beigene from $312.00 to $311.00 and set an “outperform” rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Beigene from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $319.00.

About Beigene

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.